Adalimumab for early rheumatoid arthritis

References

• Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum.27(8), 864–872 (1984).
   PubMed Web of Science ®Google Scholar
• Visser H, le Cessie S, Vos K et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum.46(2), 357–365 (2002).
   PubMed Web of Science ®Google Scholar
• Machold KP, Stamm TA, Nell VK et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology46(20), 342–350 (2007).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52(11), 3381–3390 (2005).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med.130(6), 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med.340(4), 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet354(9194), 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48(1), 35–45 (2003); erratum appears in Arthritis Rheum.48(3), 855 (2003).
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum.50(5), 1400–1411 (2004).
   PubMed Web of Science ®Google Scholar
• Guidelines for the Management of Rheumatoid Arthritis. Update. American College of Rheumatology. Arthritis Rheum.46(2), 328–346 (2002).
   PubMed Web of Science ®Google Scholar
• Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford)39(Suppl. 1), 24–29 (200).
   Google Scholar
• Landewe RBM, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum.46(2), 347–356 (2002).
   PubMed Web of Science ®Google Scholar
• Tsakonas E, Fitzgerald AA, Fitzcharles MA et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J. Rheumatol.27(3), 623–629 (2000).
   PubMed Web of Science ®Google Scholar
• Mottonen T, Hannonen P, Korpela M et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum.46(4), 894–898 (2002).
   PubMed Web of Science ®Google Scholar
• Combe B, Landewe RB, Lukas C et al. Eular recommendations for the management of early arthritis report of a task force of the European Standing Committee for International Clinical Studies including therapeutics (ESCISIT). Ann. Rheum. Dis.66, 34–45 (2007).
   PubMed Web of Science ®Google Scholar
• Adalimumab. PI; prescribing information. North Chicago, IL, USA. Abbott Laboratories, 2006.
   Google Scholar
• Emery P. Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. Drugs Today39(Suppl. B), 17–23 (2003).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med.343(22), 1586–1593 (2000); erratum appears in N. Engl. J. Med.344(3), 240 (2001).
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum.50(11), 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O’Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum.52(1), 27–35 (2005).
   PubMed Web of Science ®Google Scholar
• Van Der Kooij SM. Induction of remission in patients with early rheumatoid arthritis (RA) initially treated with either prednisone or infliximab combination therapy. Presented at: American College of Rheumatology Annual Meeting. Washington, DC, USA, 10–15 November 2006 (Abstract 1306).
   Google Scholar
• Taylor PC, Steuer A, Gruber J et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum.54(1), 47–53 (2006).
   PubMed Web of Science ®Google Scholar
• McQueen FM, Benton N, Perry D et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum.48(7) 1814–1827 (2003).
   PubMed Web of Science ®Google Scholar
• Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum.56(4), 1118–1124 (2007).
   PubMed Web of Science ®Google Scholar